Send to

Choose Destination
J Manag Care Spec Pharm. 2017 Jun;23(6-b Suppl):S2-S8. doi: 10.18553/jmcp.2017.23.6-b.s2.

The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.

Author information

1 Movement Disorders Program and Department of Neurology, University of California Irvine Health, Irvine, California.
2 Chapman Global Medical Center, Orange, California; ATP Clinical Research, Costa Mesa, California; and University of California, Riverside, Orange, California.
3 Department of Neurology; Movement Disorders Program; Georgetown University Hospital National Parkinsonism Foundation Center of Excellence; and Translational Neurotherapeutics Program, Georgetown University, Washington, DC.
4 Department of Neurology and Rehabilitation Medicine, University of Cincinnati Gardner Neuroscience Institute, Cincinnati, Ohio.
5 Institute for Psychiatric Education, Dayton Psychiatric Association, Dayton, Ohio.
6 Academic Internal Medicine and Geriatrics, University of Illinois, and Jesse Brown Veterans' Center, Chicago, Illinois.
7 Movement Disorders Program and Department of Neurology, Jefferson University, Philadelphia, Pennsylvania.
8 Specialty and Pharmacy Contracts, Harvard Pilgrim Health Care, Quincy, Massachusetts.
9 Pharmacy Services, Independent Health, Buffalo, New York.
10 Health New England, Springfield, Massachusetts.
11 Magellan Rx Management, Newport, Rhode Island.


A panel of experts drawn from neurology, psychiatry, geropsychiatry, geriatrics, and pharmacy representatives of 3 health plans convened in New York City on July 30, 2016, with the objective of sharing opinions, ideas, and information regarding the optimal management of Parkinson's disease psychosis (PDP). Three key points emerged from the discussion: (1) Because of the nature of Parkinson's disease and PDP, finding appropriate treatment can prove challenging; (2) emerging therapies may present an opportunity for effective disease management; and (3) moving forward, provider and patient education regarding PDP and available treatment options is essential for well-managed symptoms and better quality of life. The panel reviewed current practices and formulated recommendations on moving forward in the treatment of PDP.


This project and manuscript was funded by ACADIA Pharmaceuticals and developed by Magellan Rx Management. Lopes and Farnum are employees of Magellan Rx Management. Kremens has received consulting/speaker fees from Teva Pharmaceuticals, UCB, Sunovion, Impax, Lundbeck, ACADIA, USWorldMeds, Merz, Acorda, Kyowa, Neurocrine, and GE Healthcare. Pagan reports consulting/speaker fees from Teva Nanoscience, AbbVie, Impax, ACADIA, Medtronic, USWorldMeds, Merz, and Cynapsus and research and educational grants from USWorldMeds, Teva, and Medtronic. Patel has received consultant/speaker fees from ACADIA, Allergen, and Avanir. Alva reports research support from Accera, Allergan, Axovant, Eisai, Neurotrope, Genentech, Intra Cellular, Janssen, Lundbeck, Neurim, Novartis, Otsuka, Roche, Suven, and Trans Tech and consultant/speaker fees from ACADIA, Alkermes, Allergan, Avanir, Janssen, Lundbeck, Merck, Nestle, Otsuka, Sunovion, Takeda, and Vanda. The other authors report no potential conflicts of interest, financial or otherwise.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Academy of Managed Care Pharmacy
Loading ...
Support Center